Sunday, October 01, 2017 8:03:52 PM
Q3 results+ YTD+ some thoughts on makret
Hi, I have not posted much on the board as it seems like Sheff and I are more focused on twitter. But I thought I would circle back to the board at the close of Q3. See results below
Highlights:
Q3 34% return
YTD 139%
Portfolio Value $3,286,924
Recap:
July through mid August was more or less flat to somewhat positive, but 2H of Q3 everything seemed to work. My patience on $VYGR, $STML, $EIGR really paid off. Traded $NEOS, $ACRX, $MRNS multiple times with big gains. Other trades that were big winners $FENC, $KURA,$RXDX,$FGEN,$FCSC, $DVAX. There were other smaller trades as well. On the negative side $VSAR was a blow up, but reasonable risk management, went into data with 2% PV position, but sold at the money calls against to lower risk. $ZGNX was also a recent loser as I played the straddle, making a profit between $2 and $28. I panicked a little bit in pre-market and covered mid 30's. I had others that did not work $EYEG, $CPRX, $AMRN...
Market is rewarding data and PDUFA runs. Seems like anything with a hard catalyst is really ripping. For example $RDHL, $CAPR, $EARS they offer a specific catalyst date they are going up 20%+ What works and what is not working always changes in the market, currently SheffStation style catalysts trades are working. Especially with tute support and hard catalyst dates.
Q4 Plays:
$STML - my largest position at 10% - I expect they will announce cohort 3 Nov 1 around the time late breaker abstracts do for ASH. I think we see mid teens and expect very good data
$BLRX - been holding this one a bit long but data Q4, I like their 8040 compound
$EARS with specific catalyst date I expect this to run to $1+ before p3 read late November.
$RXDX October data at IALSC conference 10/15-18 with great tute buying/support expect it to doe well Q4
$AGRX - PDUFA 12/26 I expect early approval, I have been trying to build a position.
$ATRS PDUFA 10/17, joining Sheff on this one
$COLL upcoming PDUFA 11/4 with high short interest, this could really run
$CRMD - expecting DSMB decision Q4 if they stop early which I think is possible, but maybe not my base case this one will rip.
$EIGR - 7% potion two big catalyst data reads, late October and JPM healthcare HDV data.
$FENC 8% position full data in two weeks at SIOP 10/14. They will have top line data on their P3 SIOPEL 6 trial, I fully expect great data and stock to revalue higher.
Q3-17
Q2-17
Q1-17
Start 2017:
*Note took posted this after week 1, so 12/31/16 value $1,250,000
-BioHunter
@TheBio_Hunter
Hi, I have not posted much on the board as it seems like Sheff and I are more focused on twitter. But I thought I would circle back to the board at the close of Q3. See results below
Highlights:
Q3 34% return
YTD 139%
Portfolio Value $3,286,924
Recap:
July through mid August was more or less flat to somewhat positive, but 2H of Q3 everything seemed to work. My patience on $VYGR, $STML, $EIGR really paid off. Traded $NEOS, $ACRX, $MRNS multiple times with big gains. Other trades that were big winners $FENC, $KURA,$RXDX,$FGEN,$FCSC, $DVAX. There were other smaller trades as well. On the negative side $VSAR was a blow up, but reasonable risk management, went into data with 2% PV position, but sold at the money calls against to lower risk. $ZGNX was also a recent loser as I played the straddle, making a profit between $2 and $28. I panicked a little bit in pre-market and covered mid 30's. I had others that did not work $EYEG, $CPRX, $AMRN...
Market is rewarding data and PDUFA runs. Seems like anything with a hard catalyst is really ripping. For example $RDHL, $CAPR, $EARS they offer a specific catalyst date they are going up 20%+ What works and what is not working always changes in the market, currently SheffStation style catalysts trades are working. Especially with tute support and hard catalyst dates.
Q4 Plays:
$STML - my largest position at 10% - I expect they will announce cohort 3 Nov 1 around the time late breaker abstracts do for ASH. I think we see mid teens and expect very good data
$BLRX - been holding this one a bit long but data Q4, I like their 8040 compound
$EARS with specific catalyst date I expect this to run to $1+ before p3 read late November.
$RXDX October data at IALSC conference 10/15-18 with great tute buying/support expect it to doe well Q4
$AGRX - PDUFA 12/26 I expect early approval, I have been trying to build a position.
$ATRS PDUFA 10/17, joining Sheff on this one
$COLL upcoming PDUFA 11/4 with high short interest, this could really run
$CRMD - expecting DSMB decision Q4 if they stop early which I think is possible, but maybe not my base case this one will rip.
$EIGR - 7% potion two big catalyst data reads, late October and JPM healthcare HDV data.
$FENC 8% position full data in two weeks at SIOP 10/14. They will have top line data on their P3 SIOPEL 6 trial, I fully expect great data and stock to revalue higher.
Q3-17
Q2-17
Q1-17
Start 2017:
*Note took posted this after week 1, so 12/31/16 value $1,250,000
-BioHunter
@TheBio_Hunter
-BioHunter
Twitter: @TheBio_Hunter
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
